Dermatology CRO Market Share, Overview and Insights 2028

Dermatology CRO Industry Overview

The global dermatology CRO market size was valued at USD 4.14 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.9% from 2021 to 2028.

The demand for topical dermatological drugs such as anti-infective, anti-inflammatory, local anesthetics, emollients, and cleansers to treat acne is a primary factor driving the market. Furthermore, the dermatological contract research organization (CRO) business is being propelled forward by the growing awareness regarding skin disorders, the high need for rapid diagnosis, and the growth in the prevalence of skin cancer and other skin ailments. The COVID-19 epidemic hurt the economy in 2020 and continues to influence a variety of businesses around the world. Because of the introduction of virtual clinical trials and government measures to maintain broken healthcare supply chains, the market for dermatology CRO was mostly unscathed by the pandemic’s ramifications. Furthermore, the bottleneck of clinical trials is improving as a result of continuous vaccination programs and the removal of shelter-in-place regulations. As a result, the market appears to have a bright future.

Gather more insights about the market drivers, restrains and growth of the Global Dermatology CRO Market

China dermatology CRO market size, by type, 2018 - 2028 (USD Million)

The rising cases of skin disorders across the globe are anticipated to augment the market growth over the forecast period. According to the American Academy of Dermatology Association, acne is the most common skin problem in the U.S., with up to 50 million people suffering from it each year. Atopic dermatitis affects one out of every ten persons at some point in their lives. Psoriasis affects around 7.5 million people in the U.S. Rosacea is a widespread skin condition that affects 16 million people in the U.S. Every day, more than 9,500 people in the U.S. are diagnosed with skin cancer.

The COVID-19 pandemic has highlighted the importance of virtual trials and the use of technology and software solutions. In the future years, the dermatology CRO environment is expected to be transformed by the increasing usage of machine learning-based platforms, artificial intelligence, and innovative trial designs. R&D activity is being driven by biopharmaceutical and pharmaceutical investments in novel and revolutionary therapies, such as regenerative medicine, and drug development services. Sponsors are still looking for experts and services in a variety of therapeutic areas.

Browse through Grand View Research’s Medical Devices Industry Research Reports.

  • Healthcare Contract Research Organization Market – The global healthcare contract research organization market size was valued at USD 42.3 billion in 2021 and is anticipated to expand at a compound annual growth rate (CAGR) of 6.5% from 2022 to 2030.
  • Artificial Intelligence Market – The global artificial intelligence market size was valued at USD 93.5 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 38.1% from 2022 to 2030.

Market Share Insights

  • February 2021: Icon plc entered into a definitive agreement to acquire PRA Health Sciences for around USD 12 billion. 
  • October 2019: Parexel increased its relationship with the Society for Clinical Research Sites (SCRS), The first and only global organization solely dedicated to protecting the interests of clinical research sites.

Key Companies profiled:

Some prominent players in the global dermatology CRO market include

  • Covance Inc.
  • Pharmaceutical Product Development, LLC (PPD)
  • Parexel International Corporation
  • Charles River Laboratories International, Inc.
  • Icon, Plc
  • Medidata Solutions, Inc.
  • Syneos Health
  • Pharmaron
  • GVK Biosciences Private Limited
  • Wuxi AppTec
  • PRA Health Sciences
  • CTI Clinical Trial & Consulting
  • Bioskin
  • Proinnovera
  • Biorasi
  • Javara
  • TFS

Order a free sample PDF of the Dermatology CRO Market Intelligence Study, published by Grand View Research.

Comments are closed